Kaloderm is a path-breaking biological dressing proven particulary effective on cutaneous wound healing.

Kaloderm received approval from KFDA in March 2005 for deep 2nd burn and in Jund 2010 for treatment of diabetic foot ulcer.

Kaloderm is produced according to the USFDA guideline and an often stricter standard spelled out by Korea Good Manufacturing Practice (KGMP).

To product Kaloderm, the foreskin of a Korean infant was secured in 2001 and the cartoonists were separated.

The clean and vigorous cells then underwent rigorous checks and tests during the approval process and were proven safe and effective for would healing.

All tests were performed in accordance with USFDA standards.

From this small source, tens of millions of 7.5cmx7.5cm sized Kaloderm can be produced through a sophisticated process of cloning.

Applied to the wound, Kaloderm secrets growing factors and cytokines that accelerate the wound healing process by stimulating the stem cells in the skin

surrounding the wound or in the remaining hair follicles.